STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRNA
  4. [Form 4] Moderna, Inc. Insider Trading Activity

MRNA Form 4: David Rubenstein RSUs Vest; Ownership Now 1,527 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Filing: Form 4 filed for Moderna, Inc. (MRNA) reporting the vesting and conversion of restricted stock units into common stock by Director David M. Rubenstein.

Key facts: On 08/05/2025 850 restricted stock units vested and converted one-for-one into 850 shares of common stock at a price of $0. Following the transaction, the reporting person beneficially owned 1,527 shares. The Form 4 was signed by attorney-in-fact James Dillon on 08/06/2025. The filing indicates a direct ownership form and uses transaction code M with no other transactions disclosed.

Positive

  • 850 restricted stock units vested and converted to 850 common shares on 08/05/2025
  • Form 4 was filed and signed promptly (08/06/2025) reporting the change in direct beneficial ownership
  • Post-transaction direct beneficial ownership is clearly disclosed as 1,527 shares

Negative

  • None.

Insights

TL;DR: Routine equity compensation vesting by a director; disclosed via timely Form 4 filing.

The filing documents the conversion of 850 restricted stock units into 850 common shares for Director David M. Rubenstein on 08/05/2025. The report shows direct beneficial ownership of 1,527 shares post-transaction and is signed 08/06/2025. From a governance perspective, this is a standard disclosure of executive/director compensation and ownership changes, consistent with Section 16 reporting obligations. No related-party transfers, sales, or other governance concerns are disclosed in the form.

TL;DR: Transaction reflects vesting of awarded RSUs; filing provides clear, limited impact data for investors.

The Form 4 reports the vesting and one-for-one conversion of 850 RSUs into common stock (transaction code M) at a stated price of $0, with total direct beneficial ownership of 1,527 shares after the event. The disclosure is concise and limited to the single event; no purchases, sales, or derivative activity beyond the conversion are reported. Impact on outstanding shares or material financial metrics is not provided in the filing.

Insider Rubenstein David M.
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units 850 $0.00 --
Exercise Common Stock 850 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 1,527 shares (Direct)
Footnotes (1)
  1. Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award vested in full on August 5, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubenstein David M.
(Last) (First) (Middle)
C/O MODERNA, INC.
325 BINNEY STREET
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/05/2025 M(1) 850 A (1) 1,527 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 08/05/2025 M(1) 850 (2) (2) Common Stock 850 $0 0 D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. The shares subject to this restricted stock unit award vested in full on August 5, 2025.
/s/ James Dillon, As Attorney-in-Fact 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the Form 4 for Moderna (MRNA) report?

The Form 4 reports that Director David M. Rubenstein had 850 restricted stock units vest and convert into 850 common shares on 08/05/2025.

How many shares does David M. Rubenstein beneficially own after the transaction?

The filing states he beneficially owns 1,527 shares following the reported transaction.

What was the price of the shares issued on vesting?

The conversion occurred at a price of $0 per share as reported in the Form 4.

When was the Form 4 signed and filed?

The Form 4 was signed by attorney-in-fact James Dillon on 08/06/2025 and references the transaction date 08/05/2025.

What transaction code was used on the Form 4?

The filing uses transaction code M, indicating a conversion or similar corporate action as noted in the form.